Alaunos Therapeutics, Inc. (TCRT) AI Stock Analysis
TCRT AI stock analysis summary
AI ResearchAlaunos Therapeutics, Inc. (TCRT) is a clinical-stage biotechnology company developing adoptive TCR engineered T-cell therapies for oncology. The company generated $3,000 in trailing twelve months revenue with an operating margin of -135233.3%. Alaunos holds $124,000 in cash and short-term investments as of June 30, 2026, alongside an enterprise value of $2.9M.
- Market cap
- $7.7M
- Revenue (TTM)
- $3,000
- P/E
- — fwd 18.5x
- 1Y return
- -15.2% S&P 500 16.8%
- Avg. target
- $1.75 -33.5% vs last close
Bull case
- Alaunos holds an enterprise value of $2.9M and trades at a PEG ratio of 0.58.
- The company's stock price trades 11.2% above its 200-day average as of October 16, 2026.
- Alaunos directed $1.4M to research and development expenses in FY2025 to advance its Phase I/II clinical pipeline.
Bear case
- Trailing twelve months revenue stands at $3,000 with an operating margin of -135233.3%.
- Cash and short-term investments totaled $124,000 as of June 30, 2026, alongside a current ratio of 0.77.
- The stock has declined 99.0% over the last 5 years, underperforming the S&P 500 return of 83.0%.
What Alaunos Therapeutics does
Alaunos Therapeutics, Inc., formerly known as ZIOPHARM Oncology, Inc., is a clinical-stage biotechnology company based in Houston, Texas, specializing in advanced cell therapies for oncology. The company develops adoptive TCR engineered T-cell therapies designed to target solid tumors. Its TCR Library is currently in Phase I/II clinical trials and includes ten TCRs targeting mutated KRAS, TP53, and EGFR in cancers such as non-small cell lung, colorectal, pancreatic, and ovarian cancers. Alaunos also advances the hunTR neoantigen platform and mbIL-15, while maintaining collaborations with PGEN Therapeutics, Inc., The University of Texas MD Anderson Cancer Center, and the National Cancer Institute.
Growth and profitability
Revenue dropped from $398,000 in FY2021 and $2.9M in FY2022 to $5,000 in FY2023. In FY2024, revenue was $10,000 with a net income of -$4.7M, followed by FY2025 revenue of $5,000, reflecting a decline of 50.0% and a net loss of -$4.2M. Over the 5-year period from FY2018 to FY2025, revenue recorded a CAGR of -49.1%. For the trailing twelve months ended June 30, 2026, revenue stood at $3,000 with an operating margin of -135233.3% and EPS of -$1.76. In the latest quarter ended June 30, 2026, quarterly revenue fell 25.0% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Alaunos held $124,000 in cash and short-term investments, against total assets of $1.5M and shareholders' equity of $652,000. Its current ratio was 0.77. Operating cash flow in FY2025 was -$2.9M, and free cash flow was -$3.0M. Capital expenditures totaled $98,000 in FY2025. Over a 5-year period, the company's share count increased by 69.9%.
Valuation and performance
Alaunos closed at $2.63 on October 16, 2026, resulting in a market cap of $7.7M and an enterprise value of $2.9M. Its forward P/E is 18.5x, above the median of 17.3x for its US-listed Healthcare peers. The company trades at an EV to revenue multiple of 957.9x and a price-to-book ratio of 4.6x. Over the past year, TCRT shares fell 15.2%, trailing the S&P 500 return of 16.8%. Over five years, the stock fell 99.0%, compared to an 83.0% gain for the S&P 500.
What analysts expect
Wall Street tracking indicates a mean price target of $1.75 for Alaunos Therapeutics, which is 33.5% below its last close of $2.63. In its quarterly reporting performance, the company registered 1 EPS beat over the last 4 quarters. The next earnings date for Alaunos Therapeutics is scheduled for November 13, 2026.
Key risks and what to watch
- With cash and short-term investments of $124,000 and FY2025 free cash flow of -$3.0M, the company faces severe liquidity pressures.
- Revenue fell 50.0% in FY2025 to $5,000, reflecting an absence of commercial product revenue.
- Shareholders have experienced dilution through a 69.9% increase in the share count over five years.
- The mean analyst price target of $1.75 indicates a potential downside of 33.5% from the October 16, 2026 closing price.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this TCRT AI stock analysis
This page is an AI-written research summary of Alaunos Therapeutics, Inc. (TCRT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: TCRT income statement, TCRT balance sheet, TCRT key metrics, TCRT chart. See the TCRT stock overview for the latest quote and news.
TCRT AI stock analysis FAQ
What does Alaunos Therapeutics do?
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops adoptive TCR engineered T-cell therapies targeting solid tumors.
What is TCRT's cash balance?
As of June 30, 2026, Alaunos Therapeutics held $124,000 in cash and short-term investments, with a current ratio of 0.77.
What is the analyst price target for TCRT stock?
The mean analyst price target for TCRT is $1.75, representing a 33.5% decline from its closing price of $2.63 on October 16, 2026.
Does Alaunos Therapeutics pay a dividend?
No, Alaunos Therapeutics does not pay a dividend.
When is the next earnings release for TCRT?
Alaunos Therapeutics is scheduled to report its next financial results on November 13, 2026.